Phesgo and Tecentriq Performance and Approvals
Al submissions for existing products
Projects in phase II and III
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Roche
Metabolism
Neuroscience
Ophthalmology
Other
RG7446
Tecentriq + Avastin
HCC adj
RG3502
RG7601
Venclexta
r/r MM t(11:14)
Phesgo OBI
RG6264
RG7446
HER2+ BC
RG7853
Alecensa
ALK+ NSCLC adj
RG7446
Tecentriq¹
NSCLC periadj
RG7446
Lunsumio (mosun) +
RG1594
Ocrevus SC
RMS & PPMS
Tecentriq
RG7446
RG7159
SCCHN adj
Gazyva
lupus nephritis
RG7828
Tecentriq + capecitabine
TNKase
RG3625
RG7446
or carbo/gem
RG6168
stroke
Enspryng
myasthenia gravis
RG7828
TNBC
RG3648
Xolair
food allergy
Tecentriq
RG7446
RG6152
ctDNA+ high-risk MIBC
Xofluza
direct transmission
RG1594
lenalidomide
2L FL
Lunsumio (mosun) +
Polivy
2L+ DLBCL (US)
Ocrevus higher dose
RMS & PPMS
RG7159
RG7159
Kadcyla + Tecentriq
HER-2+ eBC high-risk
Tecentriq
High-risk NMIBC
Tecentriq+ lurbinectedin
1l maintenance SCLC
Gazyva
Gazyva
systemic lupus
erythematosus
Gazyva
membranous nephropathy
RG7159
pediatric nephrotic
syndrome
Vabysmo
Xofluza
RG7716
(faricimab)
RG7601
Venclexta + azacitidine
1L MDS
Enspryng
Enspryng
RG6152
BRVO/CRVO
influenza, pediatric
(0-1 year)
RG6168
RG6168
autoimmune encephalitis
MOG-AD
2023
2024
2025
Status as of April 26, 2023
Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
OBI-On-Body Delivery System, Mosun-mosunetuzumab
1filing timeline based on data from interim analysis
2026 and beyond
56View entire presentation